COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dermatomyositis and Polymyositis Registry (ADAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01637064
Recruitment Status : Unknown
Verified November 2015 by Phoenix Neurological Associates, LTD.
Recruitment status was:  Enrolling by invitation
First Posted : July 10, 2012
Last Update Posted : November 6, 2015
Information provided by (Responsible Party):
Phoenix Neurological Associates, LTD

Brief Summary:
By creating a registry, physicians will have the opportunity to understand the clinical outcomes of Myositis patients treated with Acthar. Despite the availability of clinical exams, muscle biopsies, and other testing, it is surmised that there may be a more important classification of myositis that physicians are not diagnosing which could possibly lead to improper treatment due to inaccurate diagnosis. There may be several types of immune and inflammatory myositis (IIM) that do not fit well into the typical sub classifications of myositis.

Condition or disease Intervention/treatment
Dermatomyositis Polymyositis Drug: Acthar

Detailed Description:
Retrospective and prospective data will be collected from physicians who have prescribed Acthar to myositis patients to determine what specific characteristics each patient has based on biopsy analysis, laboratory results, and clinical exams. Through biopsy analysis, subcategories of IIM will be determined and could illustrate which of these IIMs may be more responsive to Acthar therapy.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Official Title: Acthar Dermatomyositis and Polymyositis Treatment
Study Start Date : April 2013
Estimated Primary Completion Date : December 2015

Intervention Details:
  • Drug: Acthar
    Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
    Other Name: ACTH

Primary Outcome Measures :
  1. Determining if Acthar treatment improves disease progression [ Time Frame: 2 years ]
    To create and maintain a registry linking clinical information, dosing and clinical response in patients with refractory myositis and to determine if Acthar treatment improves disease progression

Secondary Outcome Measures :
  1. Subgroups may predict response to Acthar therapy [ Time Frame: 2 years ]
    To determine if there are different subgroups that can be defined myopathologically that may predict response to Acthar therapy.

Biospecimen Retention:   None Retained
This is a retrospective and prospective study

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All sites chosen are well-established universities, academic centers or private practices that specialize in neuromuscular diseases. These are physicians who have several myositis patients and who are prescribing or would prescribe Acthar to myositis patients

Inclusion Criteria:

  1. Age 18-85
  2. Male or Female
  3. Clinical or pathologic diagnosis of polymyositis or dermatomyositis
  4. Capable of providing informed consent and complying with treatment regimen

Exclusion Criteria:

  1. History of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex
  2. Recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, or sensitivity to proteins of porcine origin
  3. Any other co-morbid condition which would make completion of the trial unlikely
  4. If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness to use appropriate birth control

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01637064

Layout table for location information
United States, Arizona
PNA Center for Neurological Research
Phoenix, Arizona, United States, 85018
United States, California
Ara Dikranian MD
San Diego, California, United States, 92108
United States, Missouri
Neurology INC
Columbia, Missouri, United States, 65201
United States, New York
New York Methodist Hospital
Brooklyn, New York, United States, 11215
United States, Vermont
University of Vermont
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
Phoenix Neurological Associates, LTD
Layout table for investigator information
Principal Investigator: Todd D Levine, MD Phoenix Neurological Associates, LTD
Principal Investigator: Petros Efthimiou, MD New York Methodist Hospital
Principal Investigator: Ara Dikranian, MD Ara Dikranian MD
Principal Investigator: Justine Malone, MD Neurology INC
Principal Investigator: Rup Tandan, MD University of Vermont
Layout table for additonal information
Responsible Party: Phoenix Neurological Associates, LTD Identifier: NCT01637064    
Other Study ID Numbers: ADAPT
First Posted: July 10, 2012    Key Record Dates
Last Update Posted: November 6, 2015
Last Verified: November 2015
Keywords provided by Phoenix Neurological Associates, LTD:
Acthar treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Skin Diseases